Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course

Autores
Pérez Lloret, Santiago; Meza Rojas, Gloria; Menoni, María Celia; Ruiz, Gabriela; Velásquez, Carolina; Rodriguez, Hernán; Rey, Verónica; Cardinali, Daniel Pedro
Año de publicación
2012
Idioma
inglés
Tipo de recurso
artículo
Estado
versión enviada
Descripción
Fil: Pérez Lloret, Santiago. Paul Sabatier University. Pharmacology Department; Francia
Fil: Meza Rojas, Gloria. Instituto Mutual de la Salud; Paraguay
Fil: Menoni, María Celia. Hospital Central. Servicio de Endocrinología y Metabolismo; Paraguay
Fil: Ruiz, Gabriela. Centro Médico Santa Clara; Paraguay
Fil: Velásquez, Carolina. Instituto Mutual de la Salud; Paraguay
Fil: Rodriguez, Hernán. Centro Médico Santa Clara; Paraguay
Fil: Rey, Verónica. Paul Sabatier University. Pharmacology Department; Francia
Fil: Cardinali, Daniel P. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación
Abstract: Pregabalin (PGB) is an anticonvulsivant drug that binds to α2-δ subunit of the N-type voltagedependent Ca-channel (VDCC). VDCC-containing subunits appear to be involved in presynaptic regulation of neurotransmitter release. It has been shown that PGB is capable of inhibiting glutamate, noradrenaline, acetylcholine and substance P release at several different central nervous system locations including the neocortex, the amygdala, the hippocampus, the striatum, the spinal cord, the cerebellum and the habenula. PGB is approved by the United States Food and Drug Administration for the treatment of painful diabetic peripheral neuropathy, fibromyalgia, and postherpetic neuralgia, and as adjunctive therapy in adults with partial-onset seizure disorder. In Europe, pregabalin is also approved for neuropathic pain and generalized anxiety disorder. PGB effects on sleep quality and Health-related Quality of Life (HRQoL) have been studied in many clinical trials. For example, a recent meta-analysis has shown that PGB 150-600 mg/day significantly improved pain-related sleep interference in patients with neuropathic pain. HRQoL was also improved by PGB. It has been suggested that improvements on sleep or HRQoL may be correlated to PGB analgesic effects, but the magnitude of such correlation remains unknown. Therefore, we conducted the present study aiming at further exploring the correlation between changes in pain intensity, sleep quality and HRQoL after a PGB 8-week treatment course.
Fuente
Preprint del documento publicado en Clinical Neuropharmacology 2012, 35 (1)
Materia
PREGABALINA
SUEÑO
DOLOR
CALIDAD DE VIDA
SALUD
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
Repositorio Institucional (UCA)
Institución
Pontificia Universidad Católica Argentina
OAI Identificador
oai:ucacris:123456789/1624

id RIUCA_3f787a5dd8788ed0e2e8e1cd01f257c0
oai_identifier_str oai:ucacris:123456789/1624
network_acronym_str RIUCA
repository_id_str 2585
network_name_str Repositorio Institucional (UCA)
spelling Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment coursePérez Lloret, SantiagoMeza Rojas, GloriaMenoni, María CeliaRuiz, GabrielaVelásquez, CarolinaRodriguez, HernánRey, VerónicaCardinali, Daniel PedroPREGABALINASUEÑODOLORCALIDAD DE VIDASALUDFil: Pérez Lloret, Santiago. Paul Sabatier University. Pharmacology Department; FranciaFil: Meza Rojas, Gloria. Instituto Mutual de la Salud; ParaguayFil: Menoni, María Celia. Hospital Central. Servicio de Endocrinología y Metabolismo; ParaguayFil: Ruiz, Gabriela. Centro Médico Santa Clara; ParaguayFil: Velásquez, Carolina. Instituto Mutual de la Salud; ParaguayFil: Rodriguez, Hernán. Centro Médico Santa Clara; ParaguayFil: Rey, Verónica. Paul Sabatier University. Pharmacology Department; FranciaFil: Cardinali, Daniel P. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e InvestigaciónAbstract: Pregabalin (PGB) is an anticonvulsivant drug that binds to α2-δ subunit of the N-type voltagedependent Ca-channel (VDCC). VDCC-containing subunits appear to be involved in presynaptic regulation of neurotransmitter release. It has been shown that PGB is capable of inhibiting glutamate, noradrenaline, acetylcholine and substance P release at several different central nervous system locations including the neocortex, the amygdala, the hippocampus, the striatum, the spinal cord, the cerebellum and the habenula. PGB is approved by the United States Food and Drug Administration for the treatment of painful diabetic peripheral neuropathy, fibromyalgia, and postherpetic neuralgia, and as adjunctive therapy in adults with partial-onset seizure disorder. In Europe, pregabalin is also approved for neuropathic pain and generalized anxiety disorder. PGB effects on sleep quality and Health-related Quality of Life (HRQoL) have been studied in many clinical trials. For example, a recent meta-analysis has shown that PGB 150-600 mg/day significantly improved pain-related sleep interference in patients with neuropathic pain. HRQoL was also improved by PGB. It has been suggested that improvements on sleep or HRQoL may be correlated to PGB analgesic effects, but the magnitude of such correlation remains unknown. Therefore, we conducted the present study aiming at further exploring the correlation between changes in pain intensity, sleep quality and HRQoL after a PGB 8-week treatment course.Lippincott, Williams & Wilkins2012info:eu-repo/semantics/articleinfo:eu-repo/semantics/submittedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://repositorio.uca.edu.ar/handle/123456789/16240362-56641537-162X (online)10.1097/WNF.0b013e31823df2dcPérez Lloret, S., et al. Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course [en línea]. Preprint del documento publicado en Clinical Neuropharmacology 2012, 35 (1). Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1624Preprint del documento publicado en Clinical Neuropharmacology 2012, 35 (1)reponame:Repositorio Institucional (UCA)instname:Pontificia Universidad Católica Argentinaengenginfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/2025-07-03T10:55:19Zoai:ucacris:123456789/1624instacron:UCAInstitucionalhttps://repositorio.uca.edu.ar/Universidad privadaNo correspondehttps://repositorio.uca.edu.ar/oaiclaudia_fernandez@uca.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:25852025-07-03 10:55:20.003Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentinafalse
dc.title.none.fl_str_mv Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course
title Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course
spellingShingle Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course
Pérez Lloret, Santiago
PREGABALINA
SUEÑO
DOLOR
CALIDAD DE VIDA
SALUD
title_short Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course
title_full Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course
title_fullStr Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course
title_full_unstemmed Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course
title_sort Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course
dc.creator.none.fl_str_mv Pérez Lloret, Santiago
Meza Rojas, Gloria
Menoni, María Celia
Ruiz, Gabriela
Velásquez, Carolina
Rodriguez, Hernán
Rey, Verónica
Cardinali, Daniel Pedro
author Pérez Lloret, Santiago
author_facet Pérez Lloret, Santiago
Meza Rojas, Gloria
Menoni, María Celia
Ruiz, Gabriela
Velásquez, Carolina
Rodriguez, Hernán
Rey, Verónica
Cardinali, Daniel Pedro
author_role author
author2 Meza Rojas, Gloria
Menoni, María Celia
Ruiz, Gabriela
Velásquez, Carolina
Rodriguez, Hernán
Rey, Verónica
Cardinali, Daniel Pedro
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv PREGABALINA
SUEÑO
DOLOR
CALIDAD DE VIDA
SALUD
topic PREGABALINA
SUEÑO
DOLOR
CALIDAD DE VIDA
SALUD
dc.description.none.fl_txt_mv Fil: Pérez Lloret, Santiago. Paul Sabatier University. Pharmacology Department; Francia
Fil: Meza Rojas, Gloria. Instituto Mutual de la Salud; Paraguay
Fil: Menoni, María Celia. Hospital Central. Servicio de Endocrinología y Metabolismo; Paraguay
Fil: Ruiz, Gabriela. Centro Médico Santa Clara; Paraguay
Fil: Velásquez, Carolina. Instituto Mutual de la Salud; Paraguay
Fil: Rodriguez, Hernán. Centro Médico Santa Clara; Paraguay
Fil: Rey, Verónica. Paul Sabatier University. Pharmacology Department; Francia
Fil: Cardinali, Daniel P. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación
Abstract: Pregabalin (PGB) is an anticonvulsivant drug that binds to α2-δ subunit of the N-type voltagedependent Ca-channel (VDCC). VDCC-containing subunits appear to be involved in presynaptic regulation of neurotransmitter release. It has been shown that PGB is capable of inhibiting glutamate, noradrenaline, acetylcholine and substance P release at several different central nervous system locations including the neocortex, the amygdala, the hippocampus, the striatum, the spinal cord, the cerebellum and the habenula. PGB is approved by the United States Food and Drug Administration for the treatment of painful diabetic peripheral neuropathy, fibromyalgia, and postherpetic neuralgia, and as adjunctive therapy in adults with partial-onset seizure disorder. In Europe, pregabalin is also approved for neuropathic pain and generalized anxiety disorder. PGB effects on sleep quality and Health-related Quality of Life (HRQoL) have been studied in many clinical trials. For example, a recent meta-analysis has shown that PGB 150-600 mg/day significantly improved pain-related sleep interference in patients with neuropathic pain. HRQoL was also improved by PGB. It has been suggested that improvements on sleep or HRQoL may be correlated to PGB analgesic effects, but the magnitude of such correlation remains unknown. Therefore, we conducted the present study aiming at further exploring the correlation between changes in pain intensity, sleep quality and HRQoL after a PGB 8-week treatment course.
description Fil: Pérez Lloret, Santiago. Paul Sabatier University. Pharmacology Department; Francia
publishDate 2012
dc.date.none.fl_str_mv 2012
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/submittedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str submittedVersion
dc.identifier.none.fl_str_mv https://repositorio.uca.edu.ar/handle/123456789/1624
0362-5664
1537-162X (online)
10.1097/WNF.0b013e31823df2dc
Pérez Lloret, S., et al. Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course [en línea]. Preprint del documento publicado en Clinical Neuropharmacology 2012, 35 (1). Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1624
url https://repositorio.uca.edu.ar/handle/123456789/1624
identifier_str_mv 0362-5664
1537-162X (online)
10.1097/WNF.0b013e31823df2dc
Pérez Lloret, S., et al. Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course [en línea]. Preprint del documento publicado en Clinical Neuropharmacology 2012, 35 (1). Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1624
dc.language.none.fl_str_mv eng
eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Lippincott, Williams & Wilkins
publisher.none.fl_str_mv Lippincott, Williams & Wilkins
dc.source.none.fl_str_mv Preprint del documento publicado en Clinical Neuropharmacology 2012, 35 (1)
reponame:Repositorio Institucional (UCA)
instname:Pontificia Universidad Católica Argentina
reponame_str Repositorio Institucional (UCA)
collection Repositorio Institucional (UCA)
instname_str Pontificia Universidad Católica Argentina
repository.name.fl_str_mv Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentina
repository.mail.fl_str_mv claudia_fernandez@uca.edu.ar
_version_ 1836638330561757184
score 13.070432